ISLAND PHARMACEUTICALS ORD
Island Pharmaceuticals Joins Medical Countermeasures Coalition to Advance Galidesivir Against High-Priority Virus Threats
Island Pharmaceuticals (ASX: ILA) has been granted membership into the US-based Medical Countermeasures Coalition, an important milestone in its strategy to advance lead candidate galidesivir as a critical countermeasure against high-priority virus threats.
Island Pharmaceuticals Employs FDA Animal Rule in Development of Galidesivir to Counter Deadly Marburg Virus
Island Pharmaceuticals (ASX: ILA) has been granted an opportunity to advance approval of its lead candidate Galidesivir under the US Food and Drug Administration’s Animal Rule.
Island Pharmaceuticals Expedites Purchase of Galidesivir RNA Anti-Viral Program
Anti-viral drug development company Island Pharmaceuticals (ASX: ILA) has expedited its US$550,000 acquisition of the galidesivir anti-viral program from US-based BioCryst Pharmaceuticals. The move followed “considerable confidence” that Island gained in the asset from an extensive due diligence process that included a dataset review and collaboration with consultants to define a pathway for regulatory approvals. […]
Island Pharmaceuticals reports positive anti-viral results from Phase 2a of dengue fever trial
Island Pharmaceuticals (ASX: ILA) has announced that lead candidate ISLA-101 has shown positive safety and antiviral activity in a Phase 2a cohort of its PROTECT Phase 2a/b trial into the treatment of dengue fever. The trial is assessing whether the drug can prevent or reduce viremia (a medical condition where viruses enter the bloodstream) and […]